Marker Therapeutics (NASDAQ:MRKR) Research Coverage Started at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH started coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a research note published on Tuesday, Benzinga reports. The brokerage issued a buy rating and a $11.00 price target on the stock.

Marker Therapeutics Stock Down 2.1 %

Shares of MRKR traded down $0.09 during trading hours on Tuesday, hitting $4.11. The company had a trading volume of 13,189 shares, compared to its average volume of 19,919. Marker Therapeutics has a 52-week low of $1.16 and a 52-week high of $9.68. The stock’s 50 day moving average price is $4.29 and its 200 day moving average price is $3.98.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Marker Therapeutics stock. International Assets Investment Management LLC grew its position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 1,000.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,000 shares of the company’s stock after acquiring an additional 10,000 shares during the period. International Assets Investment Management LLC owned about 0.12% of Marker Therapeutics worth $60,000 as of its most recent SEC filing. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells.